« Promoter analysis of epigenetically controlled genes in bladder cancer. | Home

Epigenetic-based treatments emphasize the biologic differences of core-binding factor acute myeloid leukemias.

By admin | March 30, 2008

Serrano E, Carnicer MJ, Lasa A, Orantes V, Pena J, Brunet S, Aventn A, Sierra J, Nomdedu JF
Leuk Res (Jun 2008)

Acute myeloid leukemia (AML) is a heterogeneous group of disorders characterized by an abnormal proliferation of the myeloid precursors and a maturation block. The most common chromosomal lesions in AML are the t(8;21) and inv(16). To better understand the leukemogenic mechanism of these fusion proteins, we performed gene expression studies in samples from (8;21), AML1 mutated and inv(16) patients, as well as from the Kasumi-1 cell line and a U937 cell line expressing the AML1-ETO fusion gene. To assess the influence of associated epigenetic lesions, we performed gene expression studies in Kasumi-1 cells and cells extracted from an Inv(16) patient, both treated with demethylating and HDAC inhibitor agents. Shared deregulated genes in the different types of core-binding factor leukemias were identified. We found a tight link between Inv(16) and mutant AML1 samples. Furthermore, some of the genes deregulated by the leukemogenic process reverted to their normal expression with demethylating and HDAC inhibitor treatment, highlighting the role of chromatin remodeling processes in AML.

Related Posts:


  • Recruitment of Drosophila Polycomb-group proteins by Polycomblike, a component of a novel protein complex in larvae.
  • Lyl1 interacts with CREB1 and alters expression of CREB1 target genes.
  • Lyl1 interacts with CREB1 and alters expression of CREB1 target genes.
  • Genetic evidence that Ras-like GTPases, Gtr1p, and Gtr2p, are involved in epigenetic control of gene expression in Saccharomyces cerevisiae.
  • Coming Soon: Broad Epigenetic Product Library from Sigma-Aldrich


    • Topics: research articles |

    Comments are closed.